The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

Poynard, Thierry; Ratziu, Vlad; Naveau, Sylvie; Thabut, Dominique; Charlotte, Frédéric; Messous, Djamila; Capron, Dominique; Abella, Annie; Massard, Julien; Ngo, Yen; Munteanu, Mona; Mercadier, Anne; Manns, Michael P.; Albrecht, Janice K.

doi:10.1186/1476-5926-4-10

Cited by 307 publications

(177 citation statements)

References 51 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…It is known that the test (score from 0 to 1) gives a quantitative estimation of steatosis of different origins. The behavior of the Steato test in patients with NAFLD is more important than ultrasonography for noninvasive diagnosis of steatosis and may reduce the need of liver biopsy, particularly in patients with other risk factors [34] . Mild to moderate elevation of serum aminotransferases (ALT and AST) found in our subjects at baseline represents the most common abnormality found in patients with NAFLD [1] .…”

Section: Discussionmentioning

confidence: 99%

Silymarin in non alcoholic fatty liver disease

Cacciapuoti

Scognamiglio²,

Palumbo³

et al. 2013

WJH

107

View full text Add to dashboard Cite

AIM:This study was undertaken to evaluate the hepatic effects of silybum marianum on non alcoholic fatty liver disease (NAFLD). METHODS:In 72 patients affected by NAFLD, main metabolic, hepatic and anti-inflammatory parameters were assayed after 3 mo of a restricted diet and before silymarin treatment (twice a day orally). The brightness of liver echography texture (hepatorenal ratio brightness) was also defined at same time. These evaluations were repeated after 6 mo of treatment. RESULTS:Serum levels of some metabolic and anti-inflammatory data nonsignificantly lowered after 6 mo of silymarin. On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase were significantly (P < 0.001) reduced. Instead, the AST/ALT ratio unchanged. Finally, the hepatorenal brightness ratio, as an index of hepatic steatosis, significantly (P < 0.05) dropped. CONCLUSION:The obtained results indicate that silymarin appears to be effective to reduce the biochemical, inflammatory and ultrasonic indices of hepatic steatosis. Some parameters indicative of early stage of atherosclerosis were also lowered.

show abstract

Section: Discussionmentioning

confidence: 99%

Silymarin in non alcoholic fatty liver disease

Cacciapuoti

Scognamiglio²,

Palumbo³

et al. 2013

WJH

107

View full text Add to dashboard Cite

show abstract

“…Tests that quantify steatosis might also be clinically useful to monitor changes induced by therapy and to predict metabolic complications of liver disease. The available tests cannot be easily compared for their diagnostic performance as they have been validated against different standards: ultrasonography [69], liver biopsy [70] or magnetic resonance imaging (MRI) [71]. The fatty liver index (FLI) [69] and the lipid accumulation product (LAP) [72] predict liver steatosis in the general population and may be useful for large-scale screening in place of ultrasonography.…”

Section: Diagnosismentioning

confidence: 99%

“…The fatty liver index (FLI) [69] and the lipid accumulation product (LAP) [72] predict liver steatosis in the general population and may be useful for large-scale screening in place of ultrasonography. The SteatoTest [70] and the NAFLD score [71] have higher sensitivity than ultrasonography and may be used to quantify steatosis. Only the SteatoTest and the FLI have been independently validated [47,69,70,72,73].…”

Section: Diagnosismentioning

confidence: 99%

“…The SteatoTest [70] and the NAFLD score [71] have higher sensitivity than ultrasonography and may be used to quantify steatosis. Only the SteatoTest and the FLI have been independently validated [47,69,70,72,73]. Also available are non-invasive tests that predict fibrosis (FibroTest [74], ELF panel [75] and FibroMeter [76]) and simpler clinical scores [77,78,79].…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

ASH and NASH

Scaglioni

Ciccia

Marino

et al. 2011

Dig Dis

View full text Add to dashboard Cite

Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of chronic liver diseases (viral, autoimmune, genetic, etc.), and with an alcohol consumption ≤20–30 g/day. On the contrary, AFLD is defined as the presence of steatosis and alcohol consumption >20–30 g/day. The most common phenotypic manifestations of primary NAFLD/NASH are overweight/obesity, visceral adiposity, type 2 diabetes, hypertriglyceridemia and hypertension. The prevalence of NAFLD in the general population in Western countries is estimated to be 25–30%. The prevalence and incidence of NASH and ASH are not known because of the impossibility of performing liver biopsy in the general population. Up to 90% of alcoholics have fatty liver, and 5–15% of these subjects will develop cirrhosis over 20 years. The risk of cirrhosis increases to 30–40% in those who continue to drink alcohol. About 10–35% of alcoholics exhibit changes on liver biopsy consistent with alcoholic hepatitis. Natural histories of NASH and ASH are not completely defined, even if patients with NASH have a reduced life expectancy due to liver-related death and cardiovascular diseases. The best treatment of AFLD/ASH is to stop drinking, and the most effective first-line therapeutic option for NAFLD/NASH is non-pharmacologic lifestyle interventions through a multidisciplinary approach including weight loss, dietary changes, physical exercise, and cognitive-behavior therapy.

show abstract

“…The Steatotest, which incorporates 12 variables, showed reasonable accuracy, with a 0.79 AUROC for moderate-severe steatosis, when tested in a French cohort of more than 700 patients [27]. However, the main limits of this test are the small positive predictive value at 63% and the use of parameters not routinely available.…”

Section: Discussionmentioning

confidence: 99%

A Simple Model to Predict Moderate to Severe Steatosis in Obese Liver Donors

Martini¹,

Anty²,

Schneck³

et al. 2017

J Obes Chronic Dis

View full text Add to dashboard Cite

Background: In the selection of marginal liver grafts most transplantation centers use a cut-off of 30% macrovesicular steatosis to define an acceptable risk of non-function. The aim of this prospective cohort study was to create a noninvasive model to predict >30% hepatic steatosis based on simple clinical and biochemical markers available at the time of potential liver-donor evaluation, to avoid futile and expensive procurement proceedings.

show abstract

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

Cited by 307 publications

References 51 publications

Silymarin in non alcoholic fatty liver disease

Silymarin in non alcoholic fatty liver disease

ASH and NASH

A Simple Model to Predict Moderate to Severe Steatosis in Obese Liver Donors

Contact Info

Product

Resources

About